Veracyte director gets 5,272 restricted stock units
VERACYTE, INC. director Evan Jones received an equity award in the form of 5,272 shares of common stock on June 11, 2026, reported as a grant or other acquisition with no purchase price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
VERACYTE, INC. director Evan Jones received an equity award in the form of 5,272 shares of common stock on June 11, 2026, reported as a grant or other acquisition with no purchase price. Following this award, he directly holds 34,634 shares.
The award represents restricted stock units that vest in full on the first anniversary of the grant date or immediately before the company’s next annual stockholder meeting, whichever occurs first. The units also vest in full if there is a change in control of the issuer.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 5,272 | $0.00 | $0.00 |
Footnotes (1)
- F1. Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.
Key Figures
Key Terms
Restricted stock units financial
change in control financial
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the Veracyte (VCYT) Form 4 filing report for Evan Jones?
What type of equity did Veracyte (VCYT) grant to director Evan Jones?
When do Evan Jones’s Veracyte (VCYT) restricted stock units vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.